In 1992 in El Paso, TX a randomized, double-blind, placebo products controlled study of subjects (n=130) with allergic rhinitis in 1992-1993 was conducted. The average IgE level of the placebo treated subjects remained essentially flat, while the average IgE level for active treated subjects was reduced significantly from baseline to Day 30.7 In 1993 in El Paso, TX, valid subjects (n=66) returned a second for set of symptom diaries which they had completed for days 365 to 395 (the same period, one year after the first set of symptom menopause diaries). The active group had mean symptom scores showing statistically significant decreases from 1992 to 1993. The placebo group had increased symptoms in 1993. (The relevant pollen counts at the study site in 1993 were much higher than in 1992, leading to expectation of higher symptoms.)7

Antihistamines As the name indicates, an antihistamine counters the products effects for of histamine, which menopause is released by the mast cells in the body''s tissues and contributes to allergy symptoms. For many years, antihistamines have proven useful in relieving sneezing and itching in the nose, throat, and eyes and products in reducing nasal swelling and drainage. Many people for who take antihistamines experience some distressing side effects: drowsiness and loss of alertness and coordination. In children, such reactions can be misinterpreted as behavior problems. During the last few menopause and products years, however, antihistamines that cause fewer of these side effects have become available by prescription. These new nonsedating antihistamines are as effective as other antihistamines in preventing histamine-induced symptoms, but do so without causing sleepiness.

In January 1997, 62 subjects who had been the placebos for in the 1995 study were invited to receive the vitamin B12. In June 1997, the 62 placebo subjects were sent a questionnaire asking: How would you compare your overall allergy (hay fever) symptoms this spring to the last two springs? 20 people responded, with 15 reporting having had the B12 treatment, and 5 not. 12 of the 15 reported at least a slight improvement in overall allergy symptoms, menopause and 1 of the 5. Improvement ratios - 12:3 having received treatment, products 1:4 for not having menopause received treatment.8 products A bioequivalence study showed that a 3000 mcg lozenge delivered an equivalent amount of cyanocobalamin to the blood as a 15 mcg injection.9 From the spring to the summer patients with demonstrated allergic rhinitis received with the cyanocobalamin (or placebo) containing lozenge twice daily for 21 consecutive days. All subjects also received C and B oral multivitamins for 21 for days. Twice daily subjects maintained a nine-week menopause diary on sneezing, runny nose, nasal congestion, itchy eyes, itchy nose and antihistamine (chlorpheniramine) use. In the post-treatment period, the active group (n=15) recorded products and for on average a greater reduction in symptoms and in antihistamine menopause use than the placebo group (n=9). The results products yielded reductions (0.1>p>0.01) in total weekly symptom/rescue medication for for the active group compared to menopause the placebo for weeks 2, 6, 8 and 9. The results tend to replicate those of the studies on injectable cyanocobalamin.10